Goldman Sachs
ETON icon

Goldman Sachs’s Eton Pharmaceutcials ETON Stock Holding History

Goldman Sachs’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Sell
132,583
-84,863
-39% -$2.49M ﹤0.01% 3910
2026
Q1 		$5.37M Buy
217,446
+21,183
+11% +$370K ﹤0.01% 3626
2025
Q4 		$3.32M Buy
196,263
+6,099
+3% +$107K ﹤0.01% 4132
2025
Q3 		$4.13M Buy
190,164
+80,785
+74% +$1.34M ﹤0.01% 3822
2025
Q2 		$1.56M Sell
109,379
-65,841
-38% -$1.04M ﹤0.01% 4369
2025
Q1 		$2.27M Buy
175,220
+45,341
+35% +$685K ﹤0.01% 4045
2024
Q4 		$1.73M Buy
+129,879
New +$1.32M ﹤0.01% 4408
2024
Q3 		– Sell
-57,503
Closed -$189K – 5887
2024
Q2 		$189K Sell
57,503
-61,352
-52% -$215K ﹤0.01% 5286
2024
Q1 		$446K Buy
+118,855
New +$519K ﹤0.01% 4804
2023
Q4 		– Sell
-25,650
Closed -$107K – 5680
2023
Q3 		$107K Buy
+25,650
New +$99K ﹤0.01% 5170
2022
Q2 		– Sell
-17,610
Closed -$77K – 6519
2022
Q1 		$77K Buy
+17,610
New +$69.3K ﹤0.01% 6177
2021
Q4 		– Sell
-20,446
Closed -$103K – 6513
2021
Q3 		$103K Buy
+20,446
New +$106K ﹤0.01% 5903

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

Goldman Sachs's ETON Position: Q2 2026 in Review

Goldman Sachs reduced its Eton Pharmaceutcials (ETON) stake by 39% in Q2 2026, selling an estimated $2.49M and leaving 132,583 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3910.

Goldman Sachs first reported a position in ETON in Q3 2021 and has held it in 12 quarters since. The position peaked at $5.37M in Q1 2026. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Goldman Sachs held 132,583 shares of Eton Pharmaceutcials worth $4.8M as of Q2 2026.
  • Goldman Sachs sold 84,863 Eton Pharmaceutcials shares in Q2 2026, an estimated $2.49M.
  • Eton Pharmaceutcials made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3910 holding.
  • Goldman Sachs first reported a position in Eton Pharmaceutcials in Q3 2021 and has held it in 12 quarters since.
  • Goldman Sachs's Eton Pharmaceutcials position peaked at $5.37M in Q1 2026.
  • 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.